New sleep tablet MMH-450 enters first human safety trial

NCT ID NCT07708623

Completed Symptom relief Sponsor: Materia Medica Holding Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This Phase 1 trial evaluates the safety and tolerability of MMH-450, an experimental tablet that dissolves under the tongue, in 18 healthy adults aged 18 to 45 with normal sleep habits. Participants take the drug daily for 7 days while researchers monitor for side effects. The study does not test whether MMH-450 improves sleep, only that it is safe enough to study further.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental tablet called MMH-450, taken by mouth and dissolved under the tongue
What this could lead to: If safe, this could lead to larger studies testing whether MMH-450 improves sleep in people with sleep disorders.
What could go wrong: This is a very early, small safety study in healthy people, so it cannot yet show if the drug works for sleep problems or is safe long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SLEEP DISORDERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sleep-wake disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SLEEP DISORDERS

Contacts and locations

Show contact details

Locations

First Moscow State Medical University named after I.M. Sechenov/Center for Clinical Research of Drugs

Moscow, 119991, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.